BR112018073681A2 - análogo recombinante isolado de uma alça de fusão da proteína e de flavivírus, análogo recombinante isolado de uma proteína e de flavivírus, sequência de dna ou rna recombinante isolada, sequência de dna recombinante isolada, célula hospedeira, célula hospedeira eucariótica, método de produção de um análogo, composição, composição (vacina) imunogênica capaz de induzir uma resposta imunológica num sujeito inoculado com a referida composição, molécula de ligação, análogo, composição ou molécula de ligação, método para a proteção de um sujeito contra a infecção por um flavivírus, kit de diagnóstico, e kit teste de diagnóstico - Google Patents
análogo recombinante isolado de uma alça de fusão da proteína e de flavivírus, análogo recombinante isolado de uma proteína e de flavivírus, sequência de dna ou rna recombinante isolada, sequência de dna recombinante isolada, célula hospedeira, célula hospedeira eucariótica, método de produção de um análogo, composição, composição (vacina) imunogênica capaz de induzir uma resposta imunológica num sujeito inoculado com a referida composição, molécula de ligação, análogo, composição ou molécula de ligação, método para a proteção de um sujeito contra a infecção por um flavivírus, kit de diagnóstico, e kit teste de diagnósticoInfo
- Publication number
- BR112018073681A2 BR112018073681A2 BR112018073681-3A BR112018073681A BR112018073681A2 BR 112018073681 A2 BR112018073681 A2 BR 112018073681A2 BR 112018073681 A BR112018073681 A BR 112018073681A BR 112018073681 A2 BR112018073681 A2 BR 112018073681A2
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- isolated recombinant
- flavivirus
- analog
- protein
- Prior art date
Links
- 241000710831 Flavivirus Species 0.000 title abstract 5
- 102000004169 proteins and genes Human genes 0.000 title abstract 4
- 108090000623 proteins and genes Proteins 0.000 title abstract 4
- 230000004927 fusion Effects 0.000 title abstract 3
- 108020004511 Recombinant DNA Proteins 0.000 title 2
- 238000000034 method Methods 0.000 title 2
- 206010054261 Flavivirus infection Diseases 0.000 title 1
- 108091028043 Nucleic acid sequence Proteins 0.000 title 1
- 238000002405 diagnostic procedure Methods 0.000 title 1
- 230000028993 immune response Effects 0.000 title 1
- 230000002163 immunogen Effects 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 230000013595 glycosylation Effects 0.000 abstract 3
- 238000006206 glycosylation reaction Methods 0.000 abstract 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 abstract 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 abstract 1
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 abstract 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 150000004676 glycans Chemical class 0.000 abstract 1
- 230000012743 protein tagging Effects 0.000 abstract 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/18—Togaviridae; Flaviviridae
- C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
- C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
- G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
- G01N2333/185—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1608896.5A GB2550418A (en) | 2016-05-20 | 2016-05-20 | An improved vaccine against flaviviruses avoiding elicitation or stimulation of infection-enhancing antibodies |
| GB1608896.5 | 2016-05-20 | ||
| PCT/US2017/033882 WO2017201543A1 (en) | 2016-05-20 | 2017-05-22 | Variant flavivirus envelope sequences and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018073681A2 true BR112018073681A2 (pt) | 2019-02-26 |
Family
ID=56369688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018073681-3A BR112018073681A2 (pt) | 2016-05-20 | 2017-05-22 | análogo recombinante isolado de uma alça de fusão da proteína e de flavivírus, análogo recombinante isolado de uma proteína e de flavivírus, sequência de dna ou rna recombinante isolada, sequência de dna recombinante isolada, célula hospedeira, célula hospedeira eucariótica, método de produção de um análogo, composição, composição (vacina) imunogênica capaz de induzir uma resposta imunológica num sujeito inoculado com a referida composição, molécula de ligação, análogo, composição ou molécula de ligação, método para a proteção de um sujeito contra a infecção por um flavivírus, kit de diagnóstico, e kit teste de diagnóstico |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11028133B2 (enExample) |
| EP (2) | EP3458471B1 (enExample) |
| JP (1) | JP7121396B2 (enExample) |
| KR (1) | KR20190008896A (enExample) |
| CN (1) | CN109415414A (enExample) |
| AU (1) | AU2017268479B2 (enExample) |
| BR (1) | BR112018073681A2 (enExample) |
| CA (1) | CA3025076A1 (enExample) |
| DK (1) | DK3458471T3 (enExample) |
| GB (2) | GB2550418A (enExample) |
| HU (1) | HUE049543T2 (enExample) |
| IL (1) | IL263054A (enExample) |
| MX (1) | MX2018014198A (enExample) |
| PE (1) | PE20190130A1 (enExample) |
| PH (1) | PH12018502441A1 (enExample) |
| RU (1) | RU2018142835A (enExample) |
| SG (1) | SG11201810157QA (enExample) |
| WO (2) | WO2017201543A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2550418A (en) * | 2016-05-20 | 2017-11-22 | Laing Peter | An improved vaccine against flaviviruses avoiding elicitation or stimulation of infection-enhancing antibodies |
| EP3838290A1 (en) * | 2016-06-23 | 2021-06-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Vaccine compositions comprising an attenuated mutant zika virus |
| US11793873B2 (en) * | 2017-05-10 | 2023-10-24 | University Of Massachusetts | Bivalent dengue/hepatitis B vaccines |
| TWI658848B (zh) * | 2018-02-13 | 2019-05-11 | 國立清華大學 | 茲卡病毒疫苗組合物及其應用 |
| CN109627294B (zh) * | 2018-12-29 | 2020-10-09 | 四川大学 | 一种正确折叠的重组狂犬病毒g蛋白胞外段及其潜在应用 |
| WO2020198865A1 (en) * | 2019-04-03 | 2020-10-08 | The University Of British Columbia | Oligopeptides for quantitative viral proteomic analysis methods and uses |
| MX2022005498A (es) * | 2019-11-07 | 2022-08-11 | Inst Microbiology Cas | Vacuna del zika/dengue y aplicación de la misma. |
| AU2021357746A1 (en) * | 2020-10-07 | 2023-06-15 | Ctk Biotech, Inc. | Improved diagnostic tests |
| GB202019843D0 (en) | 2020-12-16 | 2021-01-27 | Coronex Ltd | Lateral flow tests |
| EP4602057A1 (en) * | 2022-10-11 | 2025-08-20 | University of Maryland, Baltimore | Engineered flavivirus envelope glycoprotein immunogenic compositions and methods of use |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA946122B (en) | 1993-08-17 | 1995-03-20 | Amgen Inc | Erythropoietin analogs |
| WO2007015783A2 (en) * | 2005-07-22 | 2007-02-08 | Research Development Foundation | Attenuated strains of flaviviruses , and uses thereof |
| US7943148B1 (en) * | 2007-04-04 | 2011-05-17 | The United States Of America As Represented By The Secretary Of The Army | Amino acid sites in Flavivirus E proteins useful for development of diagnostics and vaccines |
| WO2013151764A1 (en) * | 2012-04-02 | 2013-10-10 | The University Of North Carolina At Chapel Hill | Methods and compositions for dengue virus epitopes |
| GB201413086D0 (en) * | 2014-07-23 | 2014-09-03 | Imp Innovations Ltd And Inst Pasteur | Methods |
| GB2550418A (en) * | 2016-05-20 | 2017-11-22 | Laing Peter | An improved vaccine against flaviviruses avoiding elicitation or stimulation of infection-enhancing antibodies |
-
2016
- 2016-05-20 GB GB1608896.5A patent/GB2550418A/en not_active Withdrawn
-
2017
- 2017-05-22 SG SG11201810157QA patent/SG11201810157QA/en unknown
- 2017-05-22 RU RU2018142835A patent/RU2018142835A/ru not_active Application Discontinuation
- 2017-05-22 CN CN201780040802.7A patent/CN109415414A/zh active Pending
- 2017-05-22 BR BR112018073681-3A patent/BR112018073681A2/pt not_active IP Right Cessation
- 2017-05-22 KR KR1020187036317A patent/KR20190008896A/ko not_active Abandoned
- 2017-05-22 US US16/303,588 patent/US11028133B2/en not_active Expired - Fee Related
- 2017-05-22 PE PE2018003079A patent/PE20190130A1/es unknown
- 2017-05-22 EP EP17726515.4A patent/EP3458471B1/en not_active Not-in-force
- 2017-05-22 DK DK17726515.4T patent/DK3458471T3/da active
- 2017-05-22 MX MX2018014198A patent/MX2018014198A/es unknown
- 2017-05-22 HU HUE17726515A patent/HUE049543T2/hu unknown
- 2017-05-22 CA CA3025076A patent/CA3025076A1/en active Pending
- 2017-05-22 AU AU2017268479A patent/AU2017268479B2/en not_active Ceased
- 2017-05-22 JP JP2018561062A patent/JP7121396B2/ja active Active
- 2017-05-22 WO PCT/US2017/033882 patent/WO2017201543A1/en not_active Ceased
- 2017-11-22 GB GBGB1719423.4A patent/GB201719423D0/en not_active Ceased
-
2018
- 2018-05-22 EP EP18725547.6A patent/EP3630796A1/en not_active Withdrawn
- 2018-05-22 US US16/615,788 patent/US11401307B2/en active Active
- 2018-05-22 WO PCT/EP2018/063422 patent/WO2018215495A1/en not_active Ceased
- 2018-11-15 IL IL263054A patent/IL263054A/en unknown
- 2018-11-20 PH PH12018502441A patent/PH12018502441A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20200215180A1 (en) | 2020-07-09 |
| HUE049543T2 (hu) | 2020-09-28 |
| US11028133B2 (en) | 2021-06-08 |
| CN109415414A (zh) | 2019-03-01 |
| AU2017268479B2 (en) | 2021-04-01 |
| IL263054A (en) | 2019-01-31 |
| EP3458471B1 (en) | 2020-03-25 |
| WO2018215495A1 (en) | 2018-11-29 |
| RU2018142835A (ru) | 2020-06-22 |
| MX2018014198A (es) | 2019-08-21 |
| AU2017268479A1 (en) | 2018-12-06 |
| GB201719423D0 (en) | 2018-01-03 |
| PH12018502441A1 (en) | 2019-05-15 |
| EP3630796A1 (en) | 2020-04-08 |
| GB2550418A (en) | 2017-11-22 |
| EP3458471A1 (en) | 2019-03-27 |
| KR20190008896A (ko) | 2019-01-25 |
| SG11201810157QA (en) | 2018-12-28 |
| PE20190130A1 (es) | 2019-01-17 |
| JP2019520058A (ja) | 2019-07-18 |
| CA3025076A1 (en) | 2017-11-23 |
| JP7121396B2 (ja) | 2022-08-18 |
| DK3458471T3 (da) | 2020-07-06 |
| WO2017201543A1 (en) | 2017-11-23 |
| GB201608896D0 (en) | 2016-07-06 |
| US20190300580A1 (en) | 2019-10-03 |
| US11401307B2 (en) | 2022-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018073681A2 (pt) | análogo recombinante isolado de uma alça de fusão da proteína e de flavivírus, análogo recombinante isolado de uma proteína e de flavivírus, sequência de dna ou rna recombinante isolada, sequência de dna recombinante isolada, célula hospedeira, célula hospedeira eucariótica, método de produção de um análogo, composição, composição (vacina) imunogênica capaz de induzir uma resposta imunológica num sujeito inoculado com a referida composição, molécula de ligação, análogo, composição ou molécula de ligação, método para a proteção de um sujeito contra a infecção por um flavivírus, kit de diagnóstico, e kit teste de diagnóstico | |
| PH12019500954A1 (en) | Vaccine against porcine parvovirus | |
| BR112017027448A2 (pt) | vacina contra rsv | |
| ES2563646T3 (es) | Composiciones y métodos relacionados con variantes de la proteína A (SpA) | |
| BR112021005769A2 (pt) | proteínas de ligação a dll3 e métodos de uso | |
| BR112022001185A2 (pt) | Método de eliciamento de uma resposta imune administrando uma população de polimerossomos tendo um antígeno associado com uma população de polimerossomos tendo um adjuvante associado, bem como composições compreendendo as duas populações de polimerossomos | |
| PE20250757A1 (es) | Muteinas de interleucina 21 y metodos de tratamiento | |
| EP3363458A3 (en) | A peptide | |
| CL2012000119A1 (es) | Polipeptido f de virus respiratorio sincicial recombinante, composicion inmunogenica que lo comprende, uso para la preparacion de un medicamento para la profilaxis contra dicho virus. | |
| BRPI0707154B8 (pt) | composição de vacina | |
| BR112015020885A2 (pt) | polipeptídeos de ligação hiperglicosilados | |
| PE20190352A1 (es) | Proteinas de fusion gdf 15 y usos de estas | |
| AR086078A1 (es) | Proteinas de fusion y vacunas de combinacion | |
| WO2018109220A3 (en) | Novel recombinant prefusion rsv f proteins and uses thereof | |
| HK1246658A1 (zh) | 猪流行性腹泻病毒品种及其免疫原性组合物 | |
| BR112014026162A2 (pt) | Proteína de fusão ou variante da mesma, molécula de ácido nucleico, vetor de expressão, célula hospedeira, animal não humano geneticamente modificado, planta geneticamente modificada, agente terapêutico para doenças melhoradas por lactoferrina, composição farmacêutica, e, método para preparar a proteína de fusão ou variante da mesma | |
| BR112018075420A2 (pt) | melhoramento da imunogenicidade de petídeo l2 | |
| BRPI1010880A2 (pt) | polipeptídeos de hormônio de crescimento e métodos de fazer e usar os mesmos. | |
| BR112013032723A2 (pt) | antígenos amplamente reativos computacionalmente otimizados para influenza h1n1 | |
| BRPI0707779B8 (pt) | antígeno isolado, composição de vacina e método para produção de uma proteína antígeno | |
| BR112018075396A2 (pt) | anticorpo neutralizante contra dengue para uso em um método de prevenção e/ou tratamento de infecção por zika | |
| JP2019520058A5 (enExample) | ||
| BR112018007960A2 (pt) | conjugado, proteína pcrv, composição imunogênica, métodos de preparação de uma composição imunogênica, de tratamento e de produção de um bioconjugado, polinucleotídeo, vetor, célula hospedeira, e, bioconjugado. | |
| AR081809A1 (es) | Composiciones farmaceuticas que comprenden un polipeptido que comprende al menos un motivo cxxc y antigenos heterologos y usos de las mismas | |
| EP2552490A4 (en) | INFLUENZA MATRIX 2 PROTEIN ECKTOMOMAS, EXPRESSION SYSTEM THEREFOR AND USES THEREOF |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2776 DE 19/03/2024. |